Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Purple Biotech Ltd ADR
(NQ:
PPBT
)
2.810
-0.010 (-0.35%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Purple Biotech Ltd ADR
< Previous
1
2
3
4
Next >
Purple Biotech Reaches Recommended Phase 2 Dose for NT219
February 01, 2024
From
Purple Biotech Ltd.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
January 10, 2024
Via
Benzinga
Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors
December 20, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial
December 14, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
Purple Biotech: Q3 Earnings Insights
November 21, 2023
Via
Benzinga
Purple Biotech: Q1 Earnings Insights
May 16, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
December 11, 2023
Via
Benzinga
Why Green Giant Shares Are Trading Lower By Around 37%; Here Are 20 Stocks Moving Premarket
December 11, 2023
Shares of Green Giant Inc. (NASDAQ: GGE) fell sharply in pre-market trading after announcing a proposed public offering. Green Giant shares dipped 37.1% to $0.1599 in pre-market trading. Here are some...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
December 11, 2023
It's time to start the trading week with a look at the biggest pre-market stock movers worth watching for Monday morning!
Via
InvestorPlace
Purple Biotech Fortifies NT219 Patent Protection
November 02, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
Purple Biotech Announces Closing of $5 Million Registered Direct Offering
October 19, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
October 17, 2023
Via
Benzinga
Purple Biotech Announces $5 Million Registered Direct Offering
October 17, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
October 13, 2023
Via
Benzinga
Purple Biotech Reports Potential Biomarker Data Support CM24’s Mechanism of Action
October 06, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer
October 03, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
Purple Biotech to Present New CM24 Pancreatic Cancer Biomarker Data at AACR Special Conference on September 28, 2023
September 21, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
Purple Biotech Reports Second Quarter 2023 Financial Results
August 22, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Monday
July 31, 2023
On Monday, 27 stocks hit new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
July 27, 2023
During Thursday, 56 stocks hit new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
July 25, 2023
On Tuesday, 56 companies set new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
July 24, 2023
On Monday morning, 70 companies achieved new lows for the year.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 21, 2023
July 21, 2023
Via
Benzinga
Why ImmuCell Are Trading Higher; Here Are 20 Stocks Moving Premarket
July 12, 2023
Gainers Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) shares surged 131.6% to $4.03 in pre-market trading after gaining 15% on Tuesday.
Via
Benzinga
Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients
July 11, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
Purple Biotech Debuts Scientific Advisory Board
April 25, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint Inhibitors
April 19, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
Purple Biotech to Participate in Canaccord Genuity's 2023 Horizons in Oncology Virtual Conference
April 18, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
Purple Biotech Reports Temporary Medical Leave of CEO Gil Efron
March 24, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
Purple Biotech Reports Biomarker Data from CM24 Phase 1 Dose Escalation Study
March 16, 2023
From
Purple Biotech Ltd.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.